{
    "clinical_study": {
        "@rank": "122596", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy and safety of autologous\n      transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with\n      spinal cord injury"
        }, 
        "brief_title": "Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who understand and sign the consent form for this study\n\n          -  Age : 19-70\n\n          -  Clinical diagnosis of spinal cord injury(American Spinal Injury Association[ASIA]\n             Impairment Scale[AIS] grade A or B or C)\n\n          -  Duration of injury : > 3 month\n\n        Exclusion Criteria:\n\n          -  Subjects who must put on a respirator\n\n          -  Subjects who had malignant tumor within 5 years\n\n          -  Subjects with a infectious disease include HIV and hepatitis\n\n          -  Subjects who injured brain or spinal cord before spinal cord injury\n\n          -  Subjects with anemia or thrombocytopenia\n\n          -  Subjects with angina pectoris, myocardial infarction, cardiomyopathy, occlusive\n             disease, chronic renal failure, glomerular disease and chronic obstructive pulmonary\n             disease\n\n          -  Subjects with congenital or acquired immunodeficiency disorders\n\n          -  Patients with clouded consciousness or speech disorder\n\n          -  treat with cytotoxic medications(immunosuppressive drug, corticosteroid and cytotoxic\n             drug) during clinical trials\n\n          -  participating another clinical trials within 3 months\n\n          -  other serious disease or disorder that could seriously affect ability to participate\n             in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769872", 
            "org_study_id": "KSC-MSCs-SPI"
        }, 
        "intervention": {
            "description": "Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL", 
            "intervention_name": "Autologous Adipose Tissue derived MSCs Transplantation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "choth2@korea.ac.kr", 
                "last_name": "Tai-Hyoung Cho, M.D. & Ph.D.", 
                "phone": "82-10-3791-5338"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Korea University Anam Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Tai-Hyoung Cho, M.D. & Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Dong-Hyuk Park, M.D. & Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jang-Bo Lee, M.D. & Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sang-Heon Lee, M.D. & Ph.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury", 
        "overall_contact": {
            "email": "choth2@korea.ac.kr", 
            "last_name": "Tai-Hyoung Cho, M.D. & Ph.D.", 
            "phone": "82-10-3791-5338"
        }, 
        "overall_official": {
            "affiliation": "Korea University Anam Hospital", 
            "last_name": "Tai-Hyoung Cho, M.D. & Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.", 
            "measure": "ASIA (American Spinal Injury Association) scale", 
            "safety_issue": "No", 
            "time_frame": "32 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769872"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the change of treated spinal cord injury using Magnetic Resonance Imaging (MRI) at 3 and 6 months post injection of MSCs.", 
                "measure": "Magnetic Resonance Imaging", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }, 
            {
                "description": "To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.", 
                "measure": "MEP/SSEP", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }, 
            {
                "description": "To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.", 
                "measure": "ADL (activities of daily living)", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }, 
            {
                "description": "To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.", 
                "measure": "SF-36", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }, 
            {
                "description": "To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.", 
                "measure": "ODI (Oswestry Disability Questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "32 weeks"
            }
        ], 
        "source": "K-Stemcell Co Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Korea University Anam Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "K-Stemcell Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}